New Study Demonstrates AI-Powered Care Coordination Reduces Transfer Time and Improves Outcomes in Intracerebral Hemorrhage Patients

Img
Technology Neurology Hospitals Health Technology Software Managed Care Health Data Management Artificial Intelligence

Real-world data highlights how Viz.ai accelerates access to ICH treatment

New Study Demonstrates AI-Powered Care Coordination Reduces Transfer Time and Improves Outcomes in Intracerebral Hemorrhage Patients

Media Contacts
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data showcasing the impact of Viz ICH and Viz ICH Plus in optimizing care for patients with intracerebral hemorrhage (ICH). The study, “Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology,” highlights how AI-powered detection and quantification significantly reduced interhospital transfer (IHT) time, expediting treatment and improving patient outcomes.

The case study features a 47-year-old patient with a right parieto-occipital hematoma who was rapidly identified by Viz.ai and transferred through the Neuroemergencies Management and Transfer (NEMAT) program. The use of Viz ICH and Viz ICH Plus cut the interhospital transfer time nearly in half - from an average of 200 minutes to just 101 minutes in this case - allowing the patient to undergo successful surgical evacuation and experience significant neurological recovery over the following year.

“Viz ICH has transformed how we identify and triage patients with ICH,” said Christopher Kellner, MD, Director of the Intracerebral Hemorrhage Program at Mount Sinai. “By accelerating diagnosis and enabling real-time alerts across teams and hospitals, this technology streamlines the entire transfer process, ensuring patients get the care they need without unnecessary delays.”

Intracerebral hemorrhage accounts for up to 15% of all strokes and has high morbidity and mortality rates, requiring rapid diagnosis and intervention. Accurate volume measurements of brain bleeds are crucial for assessing the severity of cases, monitoring progression, and guiding treatment decisions. However, these measurements have traditionally been manual and time consuming. Radiologists, neurologists and neurosurgeons can incorporate Viz ICH and Viz ICH Plus seamlessly into their workflows to automate this process and support faster, more efficient care decisions.

In addition to reducing transfer time, AI-powered detection and quantification has demonstrated improved efficiency in clinical workflows, with faster hematoma volume estimation and more accurate assessments compared to manual methods. The study also highlights the scalability of the solution across large, complex hospital systems where specialized ICH care may only be available at select sites.

“At Viz.ai, we are committed to using AI to close the gaps in stroke care and bring faster, more accurate treatment to every patient—no matter where they first present,” said Molly Madziva Taitt, Ph.D., VP of Global Clinical Affairs at Viz.ai. “This study is a powerful example of how AI can reduce delays, support earlier interventions, and ultimately improve outcomes for patients with intracerebral hemorrhage.”

To learn more about Viz ICH Plus, visit viz.ai/hyperdensity-measurements.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.